<DOC>
	<DOCNO>NCT00750698</DOCNO>
	<brief_summary>Preclinical study show SNDX-275 able reactivate expression EGFR , E-cadherin ErbB3 expression . The combination SNDX-275 erlotinib ( EGFRi ) patient progress erlotinib show measurable activity evidence disease control rate acceptable safety profile .</brief_summary>
	<brief_title>A Phase 2 Exploratory Study Erlotinib SNDX-275 Patients With Non-small Cell Lung Carcinoma Who Are Progressing Erlotinib</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>INCLUSION : 1 . Cytologically histologically confirm NSCLC stage IIIb ( pleural effusion ) IV 2 . Disease progressing ( either response treatment subsequent relapse objective response ) erlotinib treatment , base least 2 scan ( last within 4 week study enrollment serve baseline scan patient 's screening study ) 3 . Recovered toxicity associate recent cancer treatment ( great grade 1 toxicity CTCAE scale prior baseline condition ) 4 . At least 1 measurable lesion ≥ 20mm conventional CT scan ≥ 10mm spiral CT scan 5 . ECOG performance score 0 , 1 , 2 life expectancy least 3 month 6 . Paraffinembedded tumor specimen available correlative study 7 . Male female 18 year age 8 . Hemoglobin ≥ 9.0 g/dL ; platelet ≥ 75 x 10⁹/L ; ANC ≥ 1.0 x 10⁹/L without use hematopoietic growth factor 9 . Coagulation test within normal range 10 . Bilirubin creatinine less 2 time upper limit normal institution 11 . AST ALT less 3 time upper limit normal institution 12 . Potassium , magnesium phosphorus within normal range institution ( supplementation permissible ) 13 . Willing use accept effective method contraception study ( men woman appropriate ) 3 month last dose SNDX275 14 . Patient legally acceptable representative grant write informed consent studyspecific procedure ( include special screening test ) perform EXCLUSION : 1 . Prior stem cell transplant 2 . Symptomatic CNS involvement 3 . Prior treatment HDAC inhibitor 4 . Concurrent anticancer therapy , exception radiotherapy nontarget study lesion 5 . Currently take medication ( ) prohibit medication list 6 . Systemic chemotherapy treatment investigational agent within 28 day enrollment 7 . Current use valproic acid 8 . Untreated unstable brain metastasis , take steroid condition within 4 week study drug administration 9 . Currently active second malignancy , malignancy within last 5 year cure basal squamous cell skin carcinoma , cervical carcinoma situ , superficial bladder cancer 10 . Inability swallow oral medication gastrointestinal malabsorption condition 11 . Uncontrolled infection require IV antibiotic , antiviral , antifungal , know HIV infection , active hepatitis B C infection 12 . Abnormal cardiac function define clinically significant finding ECG ( multifocal PVCs , STT wave change consistent myocardial infarction acute ischemia , QTc great 500 millisecond ) , tachycardia , leave ventricular ejection fraction le 40 % MUGA scan 13 . Another serious uncontrolled medical condition within 3 month enrollment hypertension , diabetes mellitus , suppress immune system 14 . Known hypersensitivity benzamides 15 . Morbid obesity 16 . Women currently pregnant breastfeed 17 . Patient currently enrol ( complete within 28 day ) another investigational drug study 18 . Patient unavailable onstudy followup assessment 19 . Patient kind medical , psychiatric , behavioral disorder place patient increase risk study participation compromise ability patient give write informed consent and/or comply study procedure requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>non small cell lung cancer</keyword>
</DOC>